International Journal of Drug Delivery Technology
Volume 14, Issue 3

Quantum Dots: An Emerging Approach for Lung Cancer Management

Bhawna1, Chhoti Kumari1, Yogita Ale1*, Neha Kukreti2

1Department of Pharmaceutics, Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Premnagar, Dehradun, Uttarakhand, India.

2Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India. 

Received: 15th March, 2024; Revised: 23rd April, 2024; Accepted: 13th July, 2024; Available Online: 25th September, 2024 

ABSTRACT

Nanotechnology is an empirical approach that promises hope and novel treatment possibilities for cancer. This state-of-the-art technology offers innovative methods for diagnosing and treating a variety of illnesses. Though there have been some positive advances since the discovery of quantum dots (QD) nano-transporters, these advances are still in their development, even though they have been shown to be beneficial to society. QD has shown to be incredibly suitable for bio-imaging, targeted gene delivery, pharmacological research, biosensing, photodynamic therapy, and diagnosis through its usage in natural imaging and photography. The overview’s main goal was to emphasize how important QD is for both cancer detection and therapy. The goal is to provide readers with a basic understanding of QD, including its benefits and applications in lung cancer management. Furthermore, we have discussed the many studies pertaining to cytotoxic analysis in order to demonstrate the safety of QDs. The current study provides a concise summary of the current research, fabrication methods, and applications of QD in lung cancer treatment.

Keywords: Quantum Dots, Lung cancer, diagnosis, Treatment, Imaging, Nanotechnology. International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.3.91

How to cite this article: Bhawna, Kumari C, Ale Y, Kukreti N. Quantum Dots: An Emerging Approach for Lung Cancer Management. International Journal of Drug Delivery Technology. 2024;14(3):1914-1920.

REFERENCES

  1. Siegel RL, Miller KD, Fuchs HE, Jemal Cancer statistics 2022. CA Cancer J Clin. 2022;72(1):7–33. Available from: https://doi. org/10.3322/caac.21708.
  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, JemalGlobal cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. Available from: https://doi.org/10.3322/caac.21492
  3. Kanwal M, Ding XJ, Cao Y. Familial risk for lung cancer. Oncol Lett. 2017;13(2):535-42. Available from: https://doi. org/10.3892%2Fol.2016.5518
  4. Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A, Paul . Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22(1):40. Available from: https://doi.org/10.1186/s12943-023-01740-y
  5. Groot PM, Wu CC, Carter BW, Munden The epidemiology of lung cancer. Transl Lung Cancer Res. 2018;7(3):220-233. Available from: https://doi.org/10.21037/tlcr.2018.05.06
  6. Chen JW, Dhahbhi Lung adenocarcinoma and lung squamouscell carcinoma cancer classification, biomarker identification, and gene expression analysis using overlapping feature selection methods. Nature.2021;11:13323. https://doi.org/10.1038/s41598- 021-92725-8
  7. Nooreldeen R, Bach Current and Future Development in Lung Cancer Diagnosis. Int J Mol Sci. 202;22(16):8661. Available from: https://doi.org/10.3390/ijms22168661
  8. Andolfi M, Potenza R, Capozzi R, Liparulo V, Puma F, YasufukuThe role of bronchoscopy in the diagnosis of early lung cancer: a review. J Thorac Dis 2016;8(11):3329-3337. Available from: https://doi.org/10.21037/jtd.2016.11.81
  9. Begum M, Narasimha K. Studies on Smilax perfoliata and Breynia retusa against Experimentally Induced Cancer in Swiss Albino Mice. International Journal of Pharmaceutical Quality 2024;15(1):11-19. Available from: https://doi. org/10.25258/ijpqa.15.1.02
  10. Khullar OV, Liu Y, Gillespie T, Higgins KA, Ramalingam S, Lipscomb J, Fernandez FG. Survival after sublobar resection versus lobectomy for clinical stage IA lung cancer: an analysis from the National Cancer Data Base. J Thorac Oncol. 2015; 10: 1625-1633. Available from: https://doi.org/10.1097/ jto.0000000000000664 \
  11. Dawood MN, Jamel HO. Synthesis, Characterization of New Ligand Derived from 4-aminoantipyrine and its Complexes with Few Metallic Ions and Evaluation of their Activity as International Journal of Drug Delivery Technology 12(04):1669- 1681.
  12. Kelly K, Altorki NK, Eberhardt WEE, O’Brien MER, Spigel DR, Crino L, Tsai CM, Kim JH, Cho EK, Hoffman PC, Orlov SV, Serwatowski, Wang J, Foley M, Horan JD, Sheperd FA. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double- blind, phase III J Clin Oncol. 2015; 33: 4007-4014. Available from: https://doi.org/10.1200/jco.2015.61.8918
  13. Yoon S.M. Shaikh T. Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol. 2017; 8: 1-20. Available from: https://doi.org/10.5306/ v8.i1.1
  14. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, ChiappoA, Lee KH, Wit MD, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017; 377: 1919-1929. Available from: https://doi. org/10.1056/nejmoa1709937
  15. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, ChiappoA, Lee KH, Wit MD, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018; 379: 2342-2350. Available from: https://doi. org/10.1056/nejmoa1809697
  16. Herbst R, Morgenstern D, Boshoff The biology and management of non small cell lung cancer. Nature. 2018;553(7689):446-454. Available from: https://doi.org/10.1038/nature25183
  17. Koutu V, Gupta M, Das S, Rawar DK, Kharade V, Pasricha Nanotechnology in Lung Cancer Therapeutics: A Narrative Review. Cureus. 2023; 15(1): e34245. Available from: https://doi. org/10.7759/cureus.34245
  18. Duan Y, Shen C, Zhang Y, Luo Y. Advanced diagnostic and therapeutic strategies in nanotechnology for lung cancer. Front. 2022;12:1031000. Available from: https://doi.org/10.3389/fonc.2022.1031000
  19. Wakale V, Kachave R, Gholap P, Mahajan K, Tare H. Design and Discovery of Genistein-based Drugs as a Potential Tyrosine Kinase Inhibitor for Lung Adenocarcinoma through Hybrid In-silico Methods. International Journal of Drug Delivery Technology. 2023;13(4):1422-1427. Available from: https://doi. org/10.25258/ijddt.13.4.47
  20. Nakhaei, P, Margiana, R, Bokov DO, Abdelbasset, WK, Jadidi Kouhbanani, M.A, Varma RS, Marofi F, Jarahian M, Beheshtkhoo N. Liposomes: Structure, Biomedical Applications, and Stability Parameters with Emphasis on Cholesterol. Front. Bioeng. 2021;9: 705886. Available from: https://doi. org/10.3389/fbioe.2021.705886
  21. Zangabad PS, Mirkiani S, Shahsavari S, Masoudi B, Masroor M, Hamed H, Jafari Z, Taghipour YD, Hashemi H, Karimi M, Hamblin MR. Stimulus-Responsive Liposomes as Smart Nanoplatforms for Drug Delivery Applications. Nanotechnol. Rev. 2018;7: 95–122. Available from: https://doi.org/10.1515/ ntrev-2017-0154
  22. Scioli Montoto S, Muraca G, Ruiz Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects. Front. Mol. Biosci. 2020;7: 587997. Available from: http://dx.doi.org/10.3389/fmolb.2020.587997
  23. Paliwal R, Paliwal SR, Kenwat R, Kurmi BD, Sahu MK. Solid Lipid Nanoparticles: A Review on Recent Perspectives and Patents. Expert Opin. Ther. Pat. 2020; 30: 179–194. Available from: https://doi.org/10.1080/13543776.2020.1720649
  24. Wolfbeis OS. An Overview of Nanoparticles Commonly Used in Fluorescent Chem. Soc. Rev. 2015; 444743–4768. Available from: http://dx.doi.org/10.1039/c4cs00392f
  25. Cole LE, Ross RD, Tilley JM, Vargo-Gogola T, Roeder RK. Gold Nanoparticles as Contrast Agents in X-ray Imaging and Computed Tomography. Nanomedicine 2015;10:321–341. Available from: https://doi.org/10.1002%2Fwnan.1642
  26. Mortezazadeh, T. Glucosamine Conjugated Gadolinium (III) Oxide Nanoparticles as a Novel Targeted Contrast Agent for Cancer Diagnosis in MRI. J. Biomed. Phys. Eng. 2020;10:25. Available from: https://doi.org/10.31661/jbpe.v0i0.1018
  27. Zhou T, Hang D, Li Y, Zhang J, Wu H, Wang H, Tian E, Yan J. Role of Gd2O3-doped Carbon-11-choline-lenvatinib Nanoparticles Contrast Agent PET/CT in the Diagnosis of Patients with Lung Cancer. Oncol. Lett. 2019; 19:1117–1124. Available from: https://doi.org/10.3892%2Fol.2019.11243
  28. Fang D, Jin H, Huang X, Shi Y, Liu Z, Ben PPy@Fe3O4 Nanoparticles Inhibit Tumor Growth and Metastasis Through Chemodynamic and Photothermal Therapy in Non-Small Cell Lung Cancer. Front. Chem. 2021;9:789934. Available from : https://doi.org/10.3389%2Ffchem.2021.789934
  29. Uprety B, Abrahamse Semiconductor Quantum Dots for Photodynamic Therapy: Recent Advances. Front. Chem. 2022;10, 946574. Available f rom: https://doi. org/10.3389%2Ffchem.2022.946574
  30. Haume K, Rosa S, Grellet S, Śmiałek MA, Butterworth KT, et Gold Nanoparticles for Cancer Radiotherapy: A Review. Cancer Nanotechnol. 2016;7:8. Available from: https://doi.org/10.1186/ s12645-016-0021-x
  31. Nimesh Polyethylenimine as a Promising Vector for Targeted SiRNA Delivery. Curr. Clin. Pharmacol. 2012; 7:121–130. Available from:https://doi.org/10.2174/157488412800228857
  32. Shi M, Gu A, Tu H, Huang C, et Comparing NanoparticlePolymeric Micellar Paclitaxel and Solvent-Based Paclitaxel as First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Open-Label, Randomized, Multicenter, Phase III Trial. Ann. Oncol. 2021: 32:85–96. Available from: https://doi.org/10.1016/j. annonc.2020.10.479
  33. Zuo Y, Shen W, Wang L, Wang C, Pu Study on the Mechanism of Action of Paclitaxel-Loaded Polylactic-Co-Glycolic Acid Nanoparticles in Non-Small-Cell Lung Carcinoma Cells. Comput. Math. Methods Med. 2022; 2022:1–7. Available from: https://doi.org/10.1155%2F2022%2F8524951
  34. Agrawal S, Gurjur P, Nagendran S. Carbon Quantum Dots: Properties, Synthetic Methods, Applications in Pharmaceutical and Pollutant Analysis. International Journal of Pharmaceutical Quality Assurance 14(04):1221-1230. Available from: http:// doi.org/10.25258/ijpqa.14.4.62
  35. Le N, Zhang M, Kim Quantum Dots and Their Interaction with Biological Systems. Int. J. Mol. Sci. 2022;23: 10763. Available from https://doi.org/10.3390/ijms231810763
  36. Matea CT, Mocan T, Tabaran F, Pop T, Mosteanu O, Puia C, Iancu C, Mocan Quantum dots in imaging, drug delivery and sensor applications. Int J Nanomedicine. 2017;12: 5421-543. Available from: https://doi.org/10.2147/ijn.s138624
  37. Klepárník K, Modlitbová P. Preparation and Analysis of Quantum Dots: Applications of Capillary Electrophoresis. Methods Mol Biol. 2020;2135: 55-83. Available from: https:// org/10.1007/978-1-0716-0463-2_3
  38. Jhangir M, Gilani S, et al. Quantum Dots: Next Generation of Smart Nano-systems. Pharmaceutical Nanotechnology. 2019;7: 234-245. Available from: https://doi.org/10.2174/221173850766 6190429113906
  39. El-brolsy HMEM, Hanafy NAN, El-Kemary Fighting Non- Small Lung Cancer Cells Using Optimal Functionalization of Targeted Carbon Quantum Dots Derived from Natural Sources Might Provide Potential Therapeutic and Cancer Bio Image Strategies. Int. J. Mol. Sci. 2022;23: 13283. Available from: https://doi.org/10.3390/ijms232113283
  40. Li L, Chen Y, Xu G, Liu D, Yang Z, Chen T, Wang X, Jiang W, Xue D, Lin G. In vivo Comparison of the Biodistribution and Toxicity of InP/ZnS Quantum Dots with Different Surface Int J Nanomedicine. 2020;15: 1951-1965. Available from: https://doi.org/10.2147%2FIJN.S241332
  41. Singh RD, Shandilya R, Bhargava A, Kumar R, Tiwari R, Chaudhury K, Srivastava RK, Goryacheva IY, Mishra PK. Quantum Dot Based Nano-Biosensors for Detection of Circulating Cell Free miRNAs in Lung Carcinogenesis: From Biology to Clinical Translation. Front. Genet. 2018; 9: 616. Available from: https://doi.org/10.3389/fgene.2018.00616
  42. Yang L, Lin J, et al. High-sensitivity Flouroscence detection for lung cancer CYFRA21-1 DNA based on accumulative hybridization of quantum dots. Journal of Material Chemistry2022. Available from: http://dx.doi.org/10.1039/D1TB02557K
  43. Kalkat A, Pradhan R, et Biofunctionalized Graphene quantum dots based fluorescent biosensor towards efficient detection of small cell lung cancer. ACS Apllied Biomaterials. 2020. Available from: https://doi.org/10.1021/acsabm.0c00427
  44. Woodman C, George A, et al. Applications and strategies in nanodiagnosis and nanotherapy in lung cancer. Seminars in cancer biology. 2021;69. Available from: https://doi.org/10.1016/j. 2020.02.009
  45. Ganesan S, Tan B, et Wrinkled metal based quantum sensor forIn vitro cancer diagnosis. Biosensors and Bioelectronics. 2020;151. Available from: https://doi.org/10.1016/j.bios.2019.111967
  46. Bavili N. Kiraz A. et al. Bypassing pro-survival and resistance mechanisms of autophagy in EGFR-positive lung cancer cells by targeted delivery of 5FU using theranostic Ag2S quantum
  47. Mater. Chem. B. 2019;7: 7363. Available from: http://dx.doi. org/10.1039/C9TB01602C
  48. Meng X, Chen X, Wu W, Zheng W, Deng H, Xu L, Chen W, Li Z, Peng H. Electrochemiluminescent immunoassay for the lung cancer biomarker CYFRA21-1 using MoOx quantum dots.
  49. Mikrochim Acta. 2019;186(12):855. Available from: https://doi.org/10.1007/s00604-019-3917-4
  50. Pilch J, Kowalik P, Kowalczyk A, Bujak P, Kasprzak A, Paluszkiewicz E, Augustin E, Nowicka AM. Foliate-Targeting Quantum Dots-β-Cyclodextrin Nanocarrier for Efficient Delivery of Unsymmetrical Bisacridines to Lung and Prostate Cancer Cells. J. Mol. Sci. 2022;23:1261. Available from: https://doi. org/10.3390/ijms23031261
  51. Leung Quantum dot-trastuzumab. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004. 75.
  52. Wang S, Shao J, Li Z, Ren Q, Yu XF, Liu Black Phosphorus- Based Multimodal Nanoagent: Showing Targeted Combinatory Therapeutics against Cancer Metastasis. Nano Lett. 2019;19(8):5587-5594. Available from: https://doi.org/10.1021/acs.nanolett.9b02127
  53. Mangeolle T, Yakavets I, Lequeux N, Pons T, Bezdetnaya L, Marchal The targeting ability of fluorescent quantum dots to the folate receptor rich tumors. Photodiagnosis Photodyn Ther. 2019;26: 150-156. Available from: https://doi.org/10.1016/j. pdpdt.2019.03.010
  54. Xiong J, Yuan H, Wu H, Cheng J, Yang S, Hu Black phosphorus conjugation of chemotherapeutic ginsenoside Rg3: enhancing targeted multimodal nanotheranostics against lung cancer metastasis. Drug Deliv. 2021;28(1):1748-1758. Available from: https://doi.org/10.1080/10717544.2021.1966129
  55. Tung FI , Zheng LJ , Hou KT , Chiang CS , Chen MH , Liu TY
  56. One-stop radiotherapeutic targeting of primary and distant osteosarcoma to inhibit cancer progression and metastasis using 2DG-grafted graphene quantum dots. Nanoscale. 2020;12(16):8809-8818. Available from:http://dx.doi.org/10.1039/ C9NR10823H
  57. Sharma V, Kumar V, Kumar Heterocyclic chalcone analogues as potential anticancer agents. Anticancers agents in medicinal chemistry. 2013;13(3):422-432. Available from: https://doi. org/10.2174/187152013804910424
  58. Barani M, Bilal M, Rahdar A, Arshad R, Kumar A, Hamishekar H, Kyzas GZ. Nanodiagnosis and nanotreatmnet of colorectal cancer: overview. Journal of Nanoaprticle Research. 2021(23): 1-25. Available from: https://doi.org/10.1007/s11051-020-05129-6